Swiha, Mina M.; Sutherland, Duncan E. K.; Sistani, Golmehr; Khatami, Alireza; Abazid, Rami M.; Mujoomdar, Amol; Wiseman, Daniele P.; Romsa, Jonathan G.; Reid, Robert H.; Laidley, David T. published the artcile< Survival predictors of 177Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS)>, Recommanded Product: (9Z,12Z)-Methyl octadeca-9,12-dienoate, the main research area is peptide receptor radionuclide therapy progressive neuroendocrine tumor; Lu-Dotatate; Neuroendocrine; PRRT; Prognostic factors; Survival predictors.
177Lu-Dotatate is an emerging treatment modality for patients with unresectable or metastatic well-differentiated NETs. This study examines survival predictors in patients who received 177Lu-Dotatate. A retrospective single-center review was conducted, examining 47 individuals with progressive well-differentiated NETs treated with 177Lu-Dotatate (four induction cycles of 5.5 GBq at 10-wk intervals followed by eight maintenance cycles of 3.7 GBq at 6-mo intervals). Median follow-up was 63.1 mo with a median progression-free survival (PFS) of 34.1 mo. However, median overall survival (OS) was not reached at the time of anal. The presence of ≥ 5 bone metastases (hazard ratio HR 4.33; p = 0.015), non-gastroenteropancreatic (non-GEP) NETs (HR 3.22; p = 0.025) and development of interim ascites (HR 3.15; p = 0.047) independently predicted a worse OS. Patients with chromogranin A of 1774 × upper limit of normal (ULN) had shorter OS (p < 0.001) and PFS (p = 0.004). Similarly, those with pre-existing ascites demonstrated a worse OS (p = 0.009) and PFS (p = 0.026). Liver metastases involving greater than 50% liver volume and the existence of unusual metastatic locations had a neg. impact on OS (p = 0.033) and PFS (p = 0.026), resp. High burden of skeletal and hepatic metastases, non-GEP-NETs, chromogranin A of ≥ 4 × ULN, unusual metastatic sites, pre-existing and interim ascites are predictors of poor outcomes in patients treated with 177Lu-Dotatate. These common indicators can be used for the risk stratification and identification of patients most likely to benefit from PRRT. Journal of Cancer Research and Clinical Oncology published new progress about Alpers-Huttenlocher syndrome. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Recommanded Product: (9Z,12Z)-Methyl octadeca-9,12-dienoate.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics